Capricor Therapeutics is trading at $8.94, down 5.65%, in an October 1 decline with no clear catalyst identified in available coverage. - The latest reported news was positive 24-month Duchenne data and a planned October 3 presentation; that news accompanied the September 30 rally, not a clear explanation for the decline. - Major-index moves were mixed and modest, offering no clear explanation for the drop. - Available evidence points to an unclear, company-specific intraday move rather than a confirmed catalyst.